Raymond James & Associates Buys 1,951 Shares of Repligen Co. (NASDAQ:RGEN)

Raymond James & Associates increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 3.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,119 shares of the biotechnology company’s stock after buying an additional 1,951 shares during the period. Raymond James & Associates’ holdings in Repligen were worth $6,948,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Repligen by 0.3% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock valued at $3,805,000 after buying an additional 62 shares during the last quarter. abrdn plc boosted its stake in shares of Repligen by 1.4% during the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after acquiring an additional 71 shares during the period. Commerce Bank increased its holdings in shares of Repligen by 4.5% during the 4th quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 72 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Repligen by 15.1% in the 4th quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 85 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Repligen stock opened at $146.03 on Wednesday. The stock has a fifty day moving average of $139.57 and a 200-day moving average of $161.80. The stock has a market capitalization of $8.16 billion, a P/E ratio of 584.12, a price-to-earnings-growth ratio of 5.27 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.53 EPS. On average, sell-side analysts expect that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Guggenheim began coverage on Repligen in a report on Tuesday, June 18th. They set a “neutral” rating for the company. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $188.38.

Insider Activity

In other news, CEO Anthony Hunt bought 2,000 shares of the stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $124.08 per share, with a total value of $248,160.00. Following the acquisition, the chief executive officer now directly owns 165,177 shares in the company, valued at $20,495,162.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Anthony Hunt acquired 2,000 shares of the stock in a transaction dated Friday, June 14th. The stock was bought at an average price of $124.08 per share, with a total value of $248,160.00. Following the completion of the purchase, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.